<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02393001</url>
  </required_header>
  <id_info>
    <org_study_id>IRB201400739</org_study_id>
    <nct_id>NCT02393001</nct_id>
  </id_info>
  <brief_title>Analysis of Skin Lesions for Melanoma Presence by Volatile Spectroscopy Techniques</brief_title>
  <official_title>Analysis of Skin Lesions for Melanoma Presence by Volatile Spectroscopy Techniques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine if a very sensitive chemistry lab analyzer
      can be used to smell a skin cancer (like melanoma) similar to some dogs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Types of skin cancer, like melanoma, are likely to spread and are becoming increasingly
      common. At this time, healthcare providers look at patient's skin and remove a sample of
      suspicious areas of the skin (biopsy) to test for cancer.

      This research study will inspect cotton and cloth swabs of normal skin and suspicious areas
      of the skin that are going to be biopsied just before the biopsy. The swabs will be looked at
      with a very sensitive chemistry lab analyzer to see if the lab analyzer can confirm
      conventional lab test findings.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">October 3, 2017</completion_date>
  <primary_completion_date type="Actual">September 30, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the off line spectral analyses of saline and alcohol skin swabs of normal control, melanoma negative and melanoma positive skin biopsies.</measure>
    <time_frame>1 day</time_frame>
    <description>Determine if the melanomas have unique identifying spectra that might be applied to noninvasive melanoma skin cancer screening in lieu of taking a biopsy</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Dermatology patients</arm_group_label>
    <description>Patients seen in the dermatology clinic with suspicious skin lesion to be biopsied will have 4 skin swabs, 2 of the skin lesion and 2 of an area of unafflicted skin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dermatology patients</intervention_name>
    <description>Cleanse an area of unafflicted (control) skin with a cotton 2 x 2 dampened with saline.</description>
    <arm_group_label>Dermatology patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dermatology patients</intervention_name>
    <description>Cleanse a suspicious lesion (potential melanoma) with a saline cotton swab.</description>
    <arm_group_label>Dermatology patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dermatology patients</intervention_name>
    <description>This intervention follows the standard of care for patients with a suspicious skin lesion (potential melanoma) the physician plans to biopsy. The alcohol swab used to prep the site will be stored for testing rather than discarded.</description>
    <arm_group_label>Dermatology patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dermatology patients</intervention_name>
    <description>Cleanse an area of unafflicted (control) skin with an alcohol swab.</description>
    <arm_group_label>Dermatology patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients seen in the dermatology clinic with suspicious skin lesion to be biopsied will
        have 4 skin swabs, 2 of the skin lesion and 2 of an area of unafflicted skin
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  Seen at the dermatology clinic &amp; determined to need a skin biopsy of a suspicious
             lesion

        Exclusion Criteria:

          -  &lt; 18 years of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nikolaus Gravenstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Jerome H. Modell, MD, Professor of Anesthesiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UF Health</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-3003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2015</study_first_submitted>
  <study_first_submitted_qc>March 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2015</study_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>skin cancer</keyword>
  <keyword>suspicious lesion</keyword>
  <keyword>skin biopsy</keyword>
  <keyword>noninvasive</keyword>
  <keyword>screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

